Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Marcus Yountz, MD
Alexion Pharmaceuticals, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
60 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Buenos Aires, Argentina
- Facility name not stated
Edegem, Belgium
- Facility name not stated
Ghent, Belgium
- Facility name not stated
Leuven, Belgium
- Facility name not stated
São Paulo, Brazil
- Facility name not stated
Edmonton, Canada
- Facility name not stated
Ostrava - Poruba, Czechia
- Facility name not stated
Prague, Czechia
- Facility name not stated
Arhus C, Denmark
- Facility name not stated
Copenhagen, Denmark
- Facility name not stated
Turku, Finland
- Facility name not stated
Szeged, Hungary
- Facility name not stated
Milan, Italy
- Facility name not stated
Naples, Italy
- Facility name not stated
Roma, Italy
- Facility name not stated
Chiba, Japan
- Facility name not stated
Fukuoka, Japan
- Facility name not stated
Hanamaki, Japan
- Facility name not stated
Hokkaido, Japan
- Facility name not stated
Miyagi, Japan
- Facility name not stated
Nagasaki, Japan
- Facility name not stated
Osaka, Japan
- Facility name not stated
Osaka-Fu, Japan
- Facility name not stated
Amsterdam, Netherlands
- Facility name not stated
Seoul, South Korea
- Facility name not stated
Barcelona, Spain
- Facility name not stated
Madrid, Spain
- Facility name not stated
Stockholm, Sweden
- Facility name not stated
Ankara, Turkey (Türkiye)
- Facility name not stated
Izmir, Turkey (Türkiye)
- Facility name not stated
Kocaeli, Turkey (Türkiye)
- Facility name not stated
Birmingham, United Kingdom
- Facility name not stated
Liverpool, United Kingdom
- Facility name not stated
London, United Kingdom
- Facility name not stated
Birmingham, Alabama, United States
- Facility name not stated
Los Angeles, California, United States
- Facility name not stated
Orange, California, United States
- Facility name not stated
Palo Alto, California, United States
- Facility name not stated
San Francisco, California, United States
- Facility name not stated
New Haven, Connecticut, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 12 Nov 2014
- Primary completion
- 15 Jan 2019
- Completion
- 15 Jan 2019
- Last update posted
- 5 Feb 2020
- Registered enrollment
- 117
- Registry id
- NCT02301624
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.